A detailed history of Capital Performance Advisors LLP transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 7 shares of NAUT stock, worth $18. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7
Holding current value
$18
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$2.24 - $3.08 $15 - $21
7 New
7 $0

Others Institutions Holding NAUT

About Nautilus Biotechnology, Inc.


  • Ticker NAUT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,663,000
  • Market Cap $325M
  • Description
  • Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...
More about NAUT
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.